The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
 
Eiji Kikuchi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb-Ono Pharmaceutical; Chugai Pharma; Janssen; Merck/Pfizer; MSD
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb-Ono Pharmaceutical; Chugai Pharma; Ferring; Janssen; Kissei Pharmaceutical; Kyorin; Kyowa Kirin International; Merck; MSD; Nippon Kayaku; Nippon Shinyaku; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Kissei Pharmaceutical (Inst); Kyorin (Inst); Kyowa Kirin International (Inst); Nihonkayaku (Inst); Nippon Shinyaku (Inst); Otsuka (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Shilpa Gupta
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics; Nektar
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb/Medarex; EMD Serono; Foundation Medicine; Genzyme; Gilead Sciences; Merck; Natera; Pfizer; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Gilead Sciences; Seagen
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); Exelixis (Inst); Gilead Sciences (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); QED Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate author royalty
Travel, Accommodations, Expenses - Pfizer
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Janssen; Loxo/Lilly; Merck KGaA; MSD Oncology; MSD Oncology (Inst); Pfizer (Inst); Pfizer/EMD Serono; Roche; Roche (Inst); Seagen; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); BMS (Inst); Exelixis (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Michiel Simon Van Der Heijden
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Research Funding - 4SC (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; MSD Oncology; Novartis; Roche
 
Jens Bedke
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck KGaA; MSD Oncology; Pfizer; Roche
Speakers' Bureau - Apogepha; Astellas Pharma; Bristol-Myers Squibb; Ipsen; Merck KGaA; MSD Oncology; Pfizer
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SeaGen (Inst)
 
Begoña Pérez Valderrama
Honoraria - AAA HealthCare; Astellas Pharma; Bayer; Bristol-Myers Squibb/Medarex; EUSA Pharma; Ipsen; Merck; Merck/Pfizer; MSD Oncology; Pfizer
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZeneca; Bayer; Bayer; Bristol-Myers Squibb/Medarex; MSD Oncology; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck/Pfizer
 
Aude Flechon
Honoraria - AAA HealthCare; Astellas Pharma; AstraZeneca; Bayer; BMS; Gilead Sciences; Ipsen; Janssen-Cilag; MSD Oncology; NOVARTIS; PFIZER; Roche/Genentech; Sanofi/Aventis
Travel, Accommodations, Expenses - AAA HealthCare; Astellas Pharma; AstraZeneca; Bayer; BMS; IPSEN; Janssen-Cilag; MSD Oncology; Pfizer; Roche/Genentech; Sanofi/Aventis
 
Daniel P. Petrylak
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Gilead Sciences; Incyte; Ipsen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Regeneron; Roche; Seagen; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Expert Testimony - Celgene; sanofi
 
Maria De Santis
Honoraria - AAA HealthCare; Accord Healthcare; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Basilea; Bayer; BioClin Therapeutics; Bristol-Myers Squibb; Exelixis/Ipsen; Ferring; Gilead Sciences; Immunomedics; Ipsen; Janssen-Cilag; Merck Serono; Merck Sharp & Dohme; MSD Oncology; Novartis; Orion; Pfizer; Roche/Genentech; Sandoz-Novartis; Sanofi; Seagen; Thermosome
Consulting or Advisory Role - AAA HealthCare; Accord Healthcare; Amgen; Astellas Pharma; AstraZeneca; Basilea; Bayer; BioClin Therapeutics; BioSyn Healthy Pharma; Bristol-Myers Squibb; Ferring; Gilead Sciences; GlaxoSmithKline; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Orion Health; Pierre Fabre; Roche/Genentech; Sandoz-Novartis; Sanofi; Seagen; Takeda
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Roche; Roche/Genentech; Sanofi
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Abbvie; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Curis; Daiichi Sankyo Europe GmbH; EMD Serono; Gilead Sciences; Janssen; Merck; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Jae Lyun Lee
Stock and Other Ownership Interests - Amgen; Black Diamond Therapeutics; Innovent Biologics; Johnson & Johnson/Janssen; Karyopharm Therapeutics; Merck; Zymeworks
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Merck; Novartis
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Eutilex (Inst); GI Innovation (Inst); Janssen (Inst); LG Chem (Inst); Loxo/Lilly (Inst); Merck KGaA (Inst); MSD (Inst); Novartis (Inst); Oscotec (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Umang Swami
Consulting or Advisory Role - Adaptimmune; Astellas Pharma; AstraZeneca; Exelixis; Gilead Sciences; Imvax; Pfizer; Sanofi; Seagen
Research Funding - Exelixis (Inst); Janssen (Inst); Seattle Genetics/Astellas (Inst)
 
Srikala S. Sridhar
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst)
Research Funding - Bayer (Inst); Janssen (Inst); Pfizer (Inst)
 
Ugo De Giorgi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dompé Farmaceutici; Eisai; Ipsen; Janssen; Merck; MSD; Novartis; Pfizer; PharmaMar
Research Funding - AstraZeneca (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca/Daiichi Sankyo; Ipsen; Merck; Pfizer
 
Phoebe Wright
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Yi-Tsung Lu
Employment - Pfizer; Seagen
Stock and Other Ownership Interests - Pfizer; Seagen
Patents, Royalties, Other Intellectual Property - US Patent No. 10823736 Method of assessing disease condition of cancer
Travel, Accommodations, Expenses - Pfizer; Seagen
 
Xuesong Guan
Employment - Mirati Therapeutics; Pfizer; Seagen; Zentalis (I)
Stock and Other Ownership Interests - Amgen; Zentalis (I)
 
Ryan Dillon
Employment - Astellas Pharma; Merck
Stock and Other Ownership Interests - Merck
 
Blanca Homet Moreno
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Thomas Powles
Honoraria - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson/Janssen; MashupMD; Merck; Merck Serono; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche